Business Description
Aequus Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
Compare
Compare
Traded in other countries / regions
AQS.Canada
•
AEQ.Germany
•
AQSZF.USA
Description
Aequus Pharmaceuticals Inc is a Canada based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. Aequus is developing a pipeline of products in neurology and psychiatry. The company's launched and pipeline products are Tacrolimus IR, Vistitan, AQS1304, AQS1303, and others.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.63 | |||||
| Equity-to-Asset | 0.05 | |||||
| Debt-to-Equity | 16.1 | |||||
| Debt-to-EBITDA | -1.17 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -15.73 | |||||
| Beneish M-Score | 4.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 3.4 | |||||
| 3-Year EBITDA Growth Rate | 34.1 | |||||
| 3-Year EPS without NRI Growth Rate | 37 | |||||
| 3-Year FCF Growth Rate | 35.8 | |||||
| 3-Year Book Growth Rate | -14.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.97 | |||||
| 9-Day RSI | 43.96 | |||||
| 14-Day RSI | 46.76 | |||||
| 6-1 Month Momentum % | -24.72 | |||||
| 12-1 Month Momentum % | -49.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.78 | |||||
| Quick Ratio | 0.71 | |||||
| Cash Ratio | 0.57 | |||||
| Days Inventory | 1168 | |||||
| Days Sales Outstanding | 92.48 | |||||
| Days Payable | 1635.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.2 | |||||
| Operating Margin % | -91.57 | |||||
| Net Margin % | -108.07 | |||||
| ROE % | -163.51 | |||||
| ROA % | -60.17 | |||||
| ROIC % | -82.49 | |||||
| ROC (Joel Greenblatt) % | -285.63 | |||||
| ROCE % | -103.72 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.81 | |||||
| PB Ratio | 45 | |||||
| EV-to-EBIT | -3.39 | |||||
| EV-to-EBITDA | -3.61 | |||||
| EV-to-Revenue | 3.05 | |||||
| EV-to-FCF | -4.28 | |||||
| Earnings Yield (Greenblatt) % | -29.5 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AQSZF
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.742 | ||
| EPS (TTM) ($) | -0.018 | ||
| Beta | 0.44 | ||
| Volatility % | 95.83 | ||
| 14-Day RSI | 46.76 | ||
| 14-Day ATR ($) | 0.003181 | ||
| 20-Day SMA ($) | 0.045101 | ||
| 12-1 Month Momentum % | -49.63 | ||
| 52-Week Range ($) | 0.0013 - 0.10434 | ||
| Shares Outstanding (Mil) | 132.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aequus Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aequus Pharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.